Currently Enrolling
Neurovations Research is looking for volunteers who experience 15 or more headaches per month to take part in a new study for migraine. There is no cost to you to join this study. All procedures and equipment are paid for.
To see if you qualify, call Neurovations at 707-252-9606 or fill out the form below and we will reach out shortly.
Dr. Eric Grigsby, CEO and Founder of Neurovations, provides detials about the RELIEV–CM2 clinical study at Neurovations Research that is evaluating a new implantable medical device used as a potential treatment to prevent and relieve migraine symptoms.
Is this study right for me?
You may be eligible for this study if your doctor has diagnosed you with chronic migraine and you meet the following criteria:
- Have had migraine for greater than 12 months
- Experience 15 or more headache days per month
- Have been treated with or considered treatment with onabolutinum toxin A and a monoclonal antibody against calcitonin gene-related peptide (CGRP) for migraine.
The RELIEV-CM study aims to assess the safety and effectiveness of the ShiraTronics Migraine Therapy System in relieving, interrupting and preventing Chronic Migraine. This therapy utilizes neuromodulation, which involves sending mild electrical pulses, known as stimulation, along nerve pathways. Stimulation is intended to interrupt or change pain signals potentially decreasing the frequency and/or pain severity assoicated with migraine attacks. The process involves placing thin wires (leads) connected to a small stimulator device beneath the skin. These leads then deliver controlled electrical pulses to the nerve pathways associated with chronic migraine. Patients can manage their therapy using an application. This innovative approach offers a new approach for individuals seeking relief from the burden of chronic migraines.
About Neurovations Research
Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.
What is a Migraine?
Migraine is a common neurological disorder that affects approximately 15% of the adult population. People living with migraines often experience recurring attacks of pulsating headaches of moderate to severe intensity that can last for 4 to 72 hours if left untreated.
Migraine is a recurrent, disabling neurological disorder with debilitating symptoms.
Symptoms include:
- Incapacitating head pain, worsened by physical activity/movement
- Pain on one or both sides of the head
- Throbbing pain or pressure-like pain
- Visual disturbances
- Sensitivity to light, sound, smells
- Nausea, dizziness
Episodic Migraine:
- 2nd leading cause of disability globally
- Affects 40 million people in the U.S., mostly women
For some patients, migraine frequncy increases leading to a chronic condition called Chronic Migraine
Chronic Migraine:
-
- Among the most disabling illnesses
- 15 or more headache days per month
- Has the same disability class as quadriplegia and acute psychosis accoring to the World Health Organization
To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.